INS and Hyperglycemia: This agreement coincides with ADA/EASD guidelines which recommend that patients on dual or triple therapy where HbA1c is above the individual target, or in those with extreme and symptomatic hyperglycemia or HbA1c > 10, insulin therapy should be initiated [2].